Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI)
$2.2000
-0.0700 ( -3.93% ) 41.4K
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.
Market Data
Open
$2.2000
Previous close
$2.2700
Volume
41.4K
Market cap
$12.95M
Day range
$2.1400 - $2.3750
52 week range
$1.0500 - $11.8905
SEC Filings
Form Type | Description | Pages | Date |
---|---|---|---|
8-k | 8K-related | 13 | Jul 30, 2024 |
4 | Insider transactions | 1 | Jul 24, 2024 |
8-k | 8K-related | 13 | Jul 19, 2024 |
8-k | 8K-related | 22 | Jun 28, 2024 |
8-k | 8K-related | 14 | Jun 26, 2024 |
4 | Insider transactions | 1 | Jun 25, 2024 |
3 | Insider transactions | 1 | Jun 25, 2024 |
8-k | 8K-related | 14 | Jun 20, 2024 |
8-k | 8K-related | 13 | Jun 04, 2024 |
4 | Insider transactions | 1 | Jun 03, 2024 |